Orientations
Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers
The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa are a good example. In 2012, the license for the Serum Institute of India’s meningitis A vaccine, MenAfriVac™, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to four days at temperatures of up to 40°C in a controlled temperature chain (CTC). This document provides countries with guidance on when and how to take advantage of this flexibility.
Auteurs
Langues
Année de publication
2013
Type
Catégories
Maladies
Organisations
CTC_PUBLICATIONS
Cette ressource apparaît sur le Thème suivant:
Cette ressource est incluse dans le tableau suivant:
EPI-CORE-MENINGITIS
Cette ressource est incluse dans le tableau suivant:
OPTIMIZE_CTC
Cette ressource apparaît sur le Thème suivant:
Cette ressource est incluse dans le tableau suivant:
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| Controlled temperature chain: Taking advantage of the true heat stability of vaccines | PATH, World Health Organization (WHO) | 2012 | Case study | Anglais, Français |
| Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers | World Health Organization (WHO) | 2013 | Guidance | Anglais, Français |
